MORPHEUS: A phase Ib/II multi-trial platform evaluating the safety and efficacy of cancer immunotherapy (CIT)-based combinations in patients (pts) with non-small cell lung cancer (NSCLC).
2018 ◽
Vol 36
(15_suppl)
◽
pp. TPS9105-TPS9105
◽
Keyword(s):